References
-
1.
Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009;69(5):1776-81. [PubMed ID: 19208848]. https://doi.org/10.1158/0008-5472.CAN-08-2242.
-
2.
Cidre-Aranaz F, Alonso J. EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. Front Oncol. 2015;5:162. [PubMed ID: 26258070]. https://doi.org/10.3389/fonc.2015.00162.
-
3.
Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2124-35. [PubMed ID: 16919776]. https://doi.org/10.1016/j.ejca.2006.05.015.
-
4.
Wong T, Goldsby RE, Wustrack R, Cash T, Isakoff MS, DuBois SG. Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer. 2015;62(11):1947-51. [PubMed ID: 26173989]. https://doi.org/10.1002/pbc.25635.
-
5.
Yasuda T, Inagaki T, Yamanouchi Y, Kawamoto K, Kohdera U, Kawasaki H, et al. A case of primary Ewing's sarcoma of the occipital bone presenting with obstructive hydrocephalus. Childs Nerv Syst. 2003;19(12):792-9. [PubMed ID: 14586633]. https://doi.org/10.1007/s00381-003-0816-z.
-
6.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27(15):2536-41. [PubMed ID: 19349548]. https://doi.org/10.1200/JCO.2008.19.1478.
-
7.
Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011;117(13):3027-32. [PubMed ID: 21692057]. https://doi.org/10.1002/cncr.25840.
-
8.
Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22(5):1221-7. [PubMed ID: 21059639]. https://doi.org/10.1093/annonc/mdq573.
-
9.
Krasin MJ, Davidoff AM, Rodriguez-Galindo C, Billups CA, Fuller CE, Neel MD, et al. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. Cancer. 2005;104(2):367-73. [PubMed ID: 15948159]. https://doi.org/10.1002/cncr.21160.
-
10.
De Ioris MA, Prete A, Cozza R, Podda M, Manzitti C, Pession A, et al. Ewing sarcoma of the bone in children under 6 years of age. PLoS One. 2013;8(1). e53223. [PubMed ID: 23382839]. https://doi.org/10.1371/journal.pone.0053223.
-
11.
Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189-95. [PubMed ID: 25595632]. https://doi.org/10.1016/j.canep.2014.12.012.
-
12.
Jurgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988;61(1):23-32. [PubMed ID: 3334950].
-
13.
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51(3):334-8. [PubMed ID: 18506764]. https://doi.org/10.1002/pbc.21618.